Rina Lokaj

Writer at ONCOLOGY journal

Featured in: Favicon

cancernetwork.com Favicon

observer.com Favicon

newsbreak.com Favicon

ajmc.com

curetoday.com Favicon

onclive.com Favicon

drugtopics.com Favicon

patientcareonline.com Favicon

targetedonc.com Favicon

urologytimes.com + 2 more

Articles

FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL

Mar 14, 2024 | cancernetwork.com | Rina Lokaj

The FDA has approved lisocabtagene maraleucel (liso-cel; Breyanzi) as a treatment for adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.1The approval is based on the data from the phase 1/2 TRANSCEND CLL 004 trial (NCT03331198), which assessed complete responses (CR) and CRs with incomplete hematologic recovery (CRi).
Early FDG PET/CT Scanning May Predict Treatment Response in Melanoma

Feb 19, 2024 | cancernetwork.com | Rina Lokaj

Early 18F-fluorodeoxyglucose (FDG)- PET/ CT imaging may identify metabolic changes that correspond with treatment response and progression-free survival (PFS) in patients with advanced melanoma receiving pembrolizumab (Keytruda), according to an observational study (NCT02791594) published in Clinical Cancer Research.1 A metabolic flare (MF) or a metabolic response (MR) was identified in 6 of 11 (55%) responders and 0 of 8 (0%) non–responders, with an objective response rate (ORR) of 100% in...
Simeone Named Director of UCSD Moores Cancer Center: “It’s an Opportunity of a Lifetime”

Jan 31, 2024 | cancernetwork.com | Rina Lokaj |Diane Simeone

Diane M. Simeone, MD, has been appointed director of the University of California San Diego (UCSD) Health Moores Cancer Center. Her new position will go into effect April 1, 2024.1In an interview with CancerNetwork®, Simeone described her excitement for this new path in her career. As an expert in pancreatic surgery as well as surgical oncology, her ambitions within this position include expanding the center’s clinical trial goals and increasing early detection of pancreatic cancer.
FDA Grants Priority Review to Alectinib for ALK+ NSCLC

Jan 29, 2024 | cancernetwork.com | Rina Lokaj

The FDA has accepted a supplemental biologics license application (sBLA) and granted priority review for the ALK inhibitor alectinib (Alecensa) as an adjuvant treatment following surgery for patients with early-stage ALK-positive non–small cell lung cancer (NSCLC).1 The decision was based on the results from the phase 3 ALINA study (NCT03456076).2 Patients who received alectinib experienced a 76% decrease in the risk of disease recurrence or death compared with patients who received...
Adjuvant Nivolumab Falls Short of Disease-Free Survival End Point in Locally Advanced High-Risk RCC

Jan 27, 2024 | newsbreak.com | Rina Lokaj

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
Adjuvant Nivolumab Misses DFS End Point in Locally Advanced High-Risk RCC

Jan 27, 2024 | cancernetwork.com | Rina Lokaj

Treatment with adjuvant nivolumab (Opdivo) monotherapy did not meet the primary end point of disease-free survival (DFS) when compared with placebo when treating patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy, according to findings from part B of the phase 3 CheckMate 914 trial (NCT03138512) presented at the 2024 Genitourinary Cancers Symposium.1 At a median follow-up of 27.0 months (95% CI, 18.0-42.4), the median DFS per blinded independent...
EMA Accepts Review for Enfortumab Vedotin Combo in Urothelial Cancer

Jan 26, 2024 | cancernetwork.com | Rina Lokaj

The European Medicines Agency (EMA) has validated a review for a type II variation application for enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for the first-line treatment of patients with previously untreated locally advanced or metastatic urothelial cancer, according to a press release from Astellas Pharma.1The application is based on results from the phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856).
Total Gastrectomy Associated with Long-term AEs in CDH1 Variants

Jan 23, 2024 | newsbreak.com | Rina Lokaj

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy
Total Gastrectomy Associated with Long-term AEs in CDH1 Variants

Jan 23, 2024 | cancernetwork.com | Rina Lokaj

Risk-reducing total gastrectomy (RRTG) is associated with long-term adverse events (AEs) in patients with pathogenic or likely pathogenic germline CDH1 P/LP variants, according to an observational study (NCT03030404) published in the Journal of Clinical Oncology.1 Despite being a common and accepted treatment for gastric cancer, the study found that 94% of the patients who received an RRTG at least 2 years before analysis reported experiencing at least 1 chronic complication, which included...
High-Dose Radiotherapy Plus Chemotherapy Is Effective in Locally Advanced NSCLC

Jan 22, 2024 | cancernetwork.com | Rina Lokaj

A combination of high-dose stereotactic ablative radiation (SABR) plus chemotherapy showed an acceptable safety profile and efficacy as a treatment for patients with locally advanced non–small cell lung cancer that is not suitable for surgery, according to a study conducted by University of California Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.1 In patients who received low-dose (n = 10), intermediate-dose (n = 9), and high-dose SABR (n = 9), the rates of 2-year local...